Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.
Volatility & Risk
Acerus Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, indicating that its stock price is 4,244% more volatile than the S&P 500.
Profitability
This table compares Acerus Pharmaceuticals and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Acerus Pharmaceuticals | -254.66% | -346.72% | -94.54% |
Cotinga Pharmaceuticals | N/A | N/A | N/A |
Institutional & Insider Ownership
0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Acerus Pharmaceuticals and Cotinga Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Acerus Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Cotinga Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares Acerus Pharmaceuticals and Cotinga Pharmaceuticals' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Acerus Pharmaceuticals | $7.38 million | 4.05 | $-18,790,000.00 | N/A | N/A |
Cotinga Pharmaceuticals | N/A | N/A | $-2,050,000.00 | N/A | N/A |
Cotinga Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.
Summary
Cotinga Pharmaceuticals beats Acerus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.